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Abstract 
Background: The identification and management of first-line antiretroviral therapy failure is a key challenge for 
human immune deficiency virus programs in resource-limited settings. Ethiopia being one of the resource-
limited countries has limited resources available for diagnosing treatment failure and monitoring patient response 
with viral load, which is the gold standard, is not feasible in this limited setting. Patients initiate treatment with 
very advanced disease. However, factors lead to treatment failure is not well understood and well-studied. 
Objective: To identify determinants of first line antiretroviral treatment failure in public hospitals of Addis 
Ababa Methods: An unmatched case control study was conducted at Addis Ababa public hospitals using record 
review. Total sample size was 309 (103 cases and 206 controls). Bivariate analysis was done and all explanatory 
variables associated with first line treatment failure with P<.05 were entered in to multivariable logistic 
regression analysis using back ward stepwise likely hood ratio method to identify independent predictors. Result: 
One hundred three cases and two hundred six controls were included in the study. Treatment interruption 
(Adjusted odds ratio 5.4, 95% confidence interval 2.33 to 12.13), base line clusters of differentiation cell count 
<50 cells/µl (Adjusted odds ratio 2.7, 95% confidence interval 1.24 to 5.64), pulmonary Tuberculosis treatment 
(Adjusted odds ratio 2.9, 95% confidence interval 1.55 to 5.34) and history of gastric problem (Adjusted odds 
ratio 6.6, 95% confidence interval 2.33 to 18.87) were all independently associated with first line antiretroviral 
treatment failure. Conclusion and Recommendation: Base line lower clusters of differentiation cell count <50 
cell/µl, treatment interruption, history of pulmonary Tuberculosis treatment during follow up time and chronic 
gastric problem were the independent predictors of first line antiretroviral treatment failure. There for Health 
professionals should pay special attention for the risk group identified.  
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1. INTRODUCTION 
About 34 million people were living with human immune deficiency virus/acquired immune deficiency 
syndrome (HIV/AIDS) in 2010 (estimates range from 30.9 to 36.9 million, 0.5% of the world population). 
Annually 58.5 million healthy life-years lost, 1.8 million Deaths per year, US$ 52.3 billion, or 0.086% of global 
gross domestic product (GDP) in damages per year and most of these (68%) lives in sub-Saharan African 
countries. Human immune deficiency virus affects mostly people in the economically productive age range, 
reducing the work-force and, in doing so, constraining development [1, 2].  
The overall growth of the global AIDS epidemic appears to have stabilized. The annual number of new HIV 
infections has been steadily declining since the late 1990s and there are fewer AIDS-related deaths due to the 
significant scale up of antiretroviral therapy over the past few years [4]. But significant challenges remain and 
treatment outcomes continue to be substantially worse. Treatment failure, whether attributable to any type of 
failure, discontinuing ART, or loss to follow-up, has been shown to increase morbidity and mortality [19]. 
However, the identification and management of first-line antiretroviral therapy (ART) failure is a key challenge 
for HIV programs in resource-limited settings [6]. Staying on a failing first-line therapy is associated with an 
increased mortality risk & consequences of early treatment failure can be significant (development of drug 
resistance limits the ability to construct new, potent and tolerable regimens in the future) [7]. 
Ethiopia has the fifth largest population of HIV infected individuals living in Africa, which accounts to 
approximately 4% of the world’s HIV/AIDS cases [9]. Adult HIV prevalence in 2010 was 2.4% (7.7% urban and 
0.9% rural) with male female ratio of 1.9% and 2.9% respectively. According to federal ministry of health of 
Ethiopia (FMOH) report, there were 1.2 million people live with HIV, and 397,818 are estimated to be in need of 
antiretroviral treatment in 2010 [10]. According to 2011 Addis Ababa health bureau, estimated HIV prevalence 
in Addis Ababa was 8.5% and 258,238 people living with HIV/AIDS (PLWHA), ever started 250,285, 76,421 
ART service users and 55,136 currently on ART [11].  
The current status of antiretroviral therapy is therefore encouraging, but significant problems remain; it is not 
devoid of unwanted secondary effects, poor absorption of anti-HIV medications, problems due to other illnesses 
or conditions, problems due to poor health before starting treatment, side effects of medications or interactions 
with other medications and substance abuse leading to poor treatment adherence and treatment failure [12,]. 
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Patients failed for first line drug are 46% more likely to fail again for 2nd line drug & attributed to the higher 
number of side effects, have greater likelihood of experiencing drug resistance and treatment fatigue as a result 
of being on treatment longer [13]. Moreover, patients need more attention and advanced monitoring system due 
to uncertainty if viral load (VL) monitoring compared to clinical or immunological monitoring affects critical 
outcomes [14] because of the association with earlier and more frequent switching to second-line regimens than 
the use of clinical/immunological monitoring strategies [15].  
However, data from ART program and global procurement systems also suggests that treatment switching has 
occurred at lower than expected rates in resource-limited settings due to low access to second-line drugs (due to 
expensiveness), difficulties in defining treatment failure in an adherent patient with no other reasons for an 
elevated VL & the development of drug resistance limits the ability to construct new, potent and tolerable 
regimens in the future. Thus; the identification and management of first-line antiretroviral therapy failure is a key 
challenge for HIV programs in resource-limited settings [3, 5, 16]. 
In resource limiting setting since there is limited availability of second line ART, switching is often not done & 
incomplete formularies limit options. Often there is no CD4 or viral load monitoring. Current 2nd line regimens 
are complex, and have difficult drug interaction especially with rifampicin impacting on the management of 
tuberculosis (TB) co-infection. Furthermore cost is an important barrier; the cost for 2nd line in 2006 was 2% of 
total cost. This condition makes difficulty in HIV treatment program especially in resource limiting countries 
like Ethiopia [7, 17, and 18]. 
Ethiopia being one of the resource-limited countries, has limited resources available for diagnosing treatment 
failure and monitoring patient response with viral load which is the gold standard, is not feasible, patients initiate 
treatment with very advanced disease [3]. However, factors lead to treatment failure is not well understood and 
well-studied especially in Ethiopia. 
Therefore the rationale of the study is identifying those risk factors for first line ART failure (that will help to 
define early predictors of treatment efficacy that permit better use of these potent drugs, avoid unnecessary side 
effects of second line drug, prevent drug resistance & decrease economic burden especially in resource limiting 
setting like Ethiopia due to the expensiveness of second line drug). It will also help as a guide for health 
professionals and higher officials to alleviate the problem & will help to Patients to develop strategies allowing 
them to take their treatment correctly.   
 
2. MATERIAL AND METHODS  
The study was conducted in Addis Ababa public hospitals at chronic HIV care. Addis Ababa has an area of 540 
square kilometer with an estimated population of 3,038,096 people (52.36% female, 47.67% male). The 
structures of organ power of the city consists of city government,10 sub cities and 116 districts with 38 hospitals 
(10 public hospitals, 2 nongovernmental (NGO), 3 defense and police ,23 private) and 27 health centers.  
ART service is being given at 55 sites (10 public hospitals, 15 private hospitals, 25 health centers & 5 NGO 
clinics) [11]. Of these sites, 9 public hospitals treating about 44,309 adult HIV infected patients were included in 
the study. The study was conducted from February 6 to March 6, 2012. 
Unmatched case control study was conducted based on medical records of patients getting ART service at 
HAART clinics in Addis Ababa public hospitals. Patients greater than or equal to 15 year old who are on second 
line drug due to treatment failure and first line drug users from Sep 2005 to Sep 2011 for cases and controls 
respectively were the study population for the study. All patients started ART in other ART site (lacks full 
information in their records), and patients with incomplete base line records were excluded in the study. 
Sample size determination and Sampling technique  
Sample size was calculated using epi info version 3.5.1 software using proportion of nevirapine based first line 
regimen among cases and controls 48.18% and 31.1% respectively [29] using 80% power with 95% CI and case 
to control ratio of 1:2. Total sample size was 309 (206 control and 103 cases). All public hospitals in Addis 
Ababa except ALERT hospital were included for the study (because private hospitals started ART service 
recently). List of patients from each hospital on ART for the past six years (Sep 2005 to Sep 2011) were 
generated from the ART dispensing tool & merged. Then sample frame for cases & controls separately was 
prepared by the principal investigator. Sampled cases & controls were selected by simple random sampling 
technique & the selected cases and controls were distributed to each hospital based on their unique ART 
registration number. 
A. Selection of cases  
List of patients for cases based on their unique ART registration number from nine hospitals were generated for 
the past six years from the ART dispensing tool which is electronic software used for dispensing ARVs but is 
able to generate reports. Then sampled cases were taken using simple random sampling technique.  
B. Selection of controls  
List of patients for controls from nine hospitals were generated for the past six years from the ART dispensing 
tool which is electronic software used for dispensing ARVs but is able to generate reports. Finally Simple 
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random sampling technique was used to select controls. 
Data collection instruments and techniques  
The patient information collecting sheet was prepared in English. It was adapted from federal ministry of health 
of Ethiopia ART guide line and ART follow up form and data were collected by record review. The collected 
data were checked by supervisors and principal investigator. Data collectors and supervisors were trained for two 
days about the objectives of the study, contents of tools and how to collect the data before the data collection. 
Data were collected by 9 trained data collectors (ART trained nurse). The principal investigator and three other 
ART trained health officers (HOs) supervised the data collection process. 
Data processing, analysis and presentation  
Data were first checked manually for completeness and consistency by supervisors & principal investigator 
during the time of data collection and rechecked again at office before data entry. Data were entered and cleaned 
using epi info version 3.5.3. Then exported to SPSS version 16.0 for analysis & descriptive statistics were done 
to summarize the data. Then bivariate analysis was done to see the association between outcome variable & 
independent variable. All explanatory variables associated with first line antiretroviral treatment failure with 
P<.05 were entered in to multivariable logistic regression analysis. However scientifically intuitive and clinically 
important variables were included in multivariable analyses though P>.05. Backward stepwise likely hood ratio 
logistic regression was used in multivariable analysis.  
Multi-collinearity test was done to check whether there are correlated independent variables or not by examining 
the values of variance inflation factor (VIF); there were no seriously correlated variables. P<.05 in multivariable 
analysis was used to declare association between independent predictors and the outcome variable. Finally 
conclusion and recommendation were made based on the findings of the study.  
Data Quality control  
To keep the quality of the study, information collecting sheet was prepared based on federal ministry of health of 
Ethiopia standard ART guide line and ART follow up form. Data collectors and supervisors were ART trained. 
Moreover, data quality also ensured during collection, entry & analysis. Training was given for data collectors 
and supervisors before data collection and there was close follow up of data collectors by supervisors and the 
principal investigator including observation of how they were collecting the recorded data.  
Strength  
The study was conducted in a context where HAART had been started for the last 6 years (Sep 2005 to Sep 2011) 
to minimize poorly record data and to include all public hospitals in the study (ART service was started in all 
public hospital level 6 years back in Ethiopia).  
Being case control study is the strength of this study. Since antiretroviral treatment failure is a rare occurrence 
but had a serious impact globally and challenge HIV prevention and control program, case control study is a best 
study design for this situation and the design enabled to see multiple exposure unlike other study designs.  
Limitation  
This study has limitation due to the method of data collection technique used; using secondary data like relaying 
on past information which can be changed subsequently. This study didn’t assess those predictors of treatment 
failure from the patient directly which limit to see whether the patients were taking the drug properly or not, had 
got shortage of drug or not and had got adequate information about the treatment from the service provider.  
Although there is a standard treatment guide line which works for all health institutions giving ART service, 
there might be a difference in quality of care & quality of service in each hospital. However, this study didn’t 
assess it. 
 
3. RESULTS AND DISCUSSION 
3.1. Socio-demographic characteristics of study population  
A total of 103 cases and 206 controls were included in the study. From these 93 (90.3%) of cases & 190 (92.2%) 
of controls were alive, 8 (7.8%) of cases & 9 (4.4%) of controls were died and 2 (1.9%) of cases &7 (3.4%) of 
controls were defaulters. The mean age at starting treatment was 37 and 36 with a standard deviation of 9 year 
for cases & controls respectively. Majorities, 55 (53.4%) of cases and 123 (59.7%) of controls were females. 
Most, 75 (72.8%) of cases and 165 (80.1%) of controls were orthodox Christian followers. Regarding to marital 
status, 44 (42.7%) of cases and 98 (47.6%) controls were married and 27 (36%) of cases and 39 (26%) of 
controls had HIV positive partner; 22 of 27 (81.2%) and 21 of 39 (53.8%) were on ART while 30 (29.1%) of 
cases and 65 (31.6%) of controls had unknown HIV status. About 32 (32%) of cases and 114 (53%) of controls 
were full time employed while 39 (37.9 %) of cases and 32 (15.5%) of controls were not working/due to ill 
health & majorities, 40 (38.8%) of cases and 79 (38.3%) of controls had finished their secondary education at the 
time of HAART initiation (Table 1). 
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3.2. Base line laboratory measures  
Among cases and controls respectively; the median (interquartile range) baseline (at HAART initiation) CD4 
count was 74 cells/µl (1–436) and 140 cells/µl (1-667). The mean (SD) white blood cell (WBC) count among 
cases was 5157 (2332) cells/mm3, while in controls was 5629 (2698) cells/mm3. The mean lymphocyte count in 
cases and controls was 25% and 31% while the mean neutrophil count among cases and controls was 38% and 
42% with mean hemoglobin level 12.3g/dl and 13.1g/dl respectively (Table 2). 
 
3.3. ARV drug related variables  
The most frequent starting regimens for cases were AZT 3TC NVP (32%), d4t 3TC NVP (26.2%), AZT 3TC 
EFV (17.5%), and d4t 3TC EFV (12.6%). Similarly d4t 3TC NVP (28.2%), AZT 3TC EFV (27.7%), AZT 3TC 
NVP (20.4%) and d4t 3TC EFV (13.1%) were the most frequent starting regimens among controls. For the 55 
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female cases and 123 female controls for whom PMTCT exposure could be determined, 8 of 55 (14.5%) and 4 
(3.3%) had received PMTCT interventions respectively (Table 3). 
 
3.4. Adherence related variables  
Majority of cases, 58 (56.3%) and 66 (32%) controls were not consistently adhered during HAART follow up. 
On the other hand, 37 (35.9%) of cases & 9 (4.4%) of controls interrupted (defaulted) HARRT. Most of the cases, 
73 (70.9%) and 158 (76.7%) controls disclosed their HIV sero-positive status during HAART initiation. The 
median (interquartile range) duration of treatment for case & controls with first line drug was 41 and 53 months 
respectively; 82 (79.6 %) of cases and 185 (89.8 %) of controls were treated for more than 24 months. Majority 
of cases, 65 (63.1%) and 154 (74.8%) of controls were not using any of the substance. However 8 (7.8%) of 
cases and 15 (7.3%) of controls used alcohol, 5 (4.9%) of cases & 1 (0.5%) of controls were smokers, 3 (2.9%) 
of cases and 7 (3.4%) of controls used soft and hard drugs, while 22 (21.4%) of cases and 29 (14.1%) of controls 
used two or more substances during the time of HAART initiation (Table 4). 
 
3.5. Base line nutritional status (BMI)  
About 48 (46.6%) of cases’ and 143 (69.4%) of controls’ body mass index (BMI) laid in the category >=18.5 
kg/m2 while 32 (31.1%) of cases’ and 45 (21.8%) of controls’ BMI laid between 16-18.4 kg/m2. The remained 
23 (22.3%) of cases’ and 18 (8.7%) of controls’ BMI laid under the category of <16kg/m2 (Table 5). 
Journal of Biology, Agriculture and Healthcare                                                                                                                                www.iiste.org 
ISSN 2224-3208 (Paper)  ISSN 2225-093X (Online) 
Vol.4, No.15, 2014 
 
6 
 
3.6. Other health problems and clinical disease mechanism related variables  
Regarding to history of opportunistic infection and other medical health problems about 39 (37.9%) of cases and 
30 (14.6%) of controls had history of opportunistic infection. About 58 (56.4%) of cases & 47 (22.8%) of 
controls had history of TB treatment; pulmonary TB treatment accounted for 91.4% and 76.5% among cases and 
controls respectively. Majority of cases, 61 (59.2%) & 66 (32%) of controls took additional medication other 
than HAART. About One fourth of the cases, 26 (25.2%) & 7 (3.4%) of controls had history of chronic diarrhea 
while 30 (29.1%) of cases & 6 (2.9%) of controls had history of chronic gastric problem.  
More than half of the cases, 57 (55.3%) & 161 (78.2%) of controls were workable in their functional status 
during the time of HAART initiation. While only 8 (3.9%) of cases & 16 (15.5%) of controls were bedridden at 
the time of HAART initiation. About 39 (37.9%) of cases & 95 (46.1%) of controls were clinically WHO stage 
III while 35 (34%) of cases & 37 (18%) of controls were WHO stage IV (Table 6). 
 
3. 7. Bivariate analyses  
3.7.1. Bivariate analysis of Socio demographic characteristics  
In a bivariate analysis of socio-demographic characteristics, none of them were associated with first line 
antiretroviral treatment failure except being Muslim in religion (Table 7). 
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3.7.2. Bivariate analyses of base line laboratory measures  
Among variables related to base line laboratory measures that are clinically important in HIV treatment program, 
base line CD4 count <50 cell/µl and base line hemoglobin level were significantly associated with treatment 
failure in a bivariate analysis ((COR 5.20, 95% CI 2.74 to 9.880 (COR 0.48, 95% CI 0.28 to 0.83)) respectively 
(Table 8). 
 
3.7.3. Bivariate analysis of ARV drug related Variables  
Among variables related to anti-retroviral drug, duration on HAART (COR 2.25, 95% CI 1.16 to 4.36), base line 
first line drug regimen (COR 1.79, 95% CI 1.10 to 2.93) and previous ART exposure (COR4.25, 95% CI 1.25 to 
14.47) were significantly associated with first line antiretroviral treatment failure in a bivariate analysis (Table 9). 
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3.7.4. Bivariate analysis of adherence related Variables  
In a bivariate analysis of adherence related variables and substance use; substance use (COR 1.73, 95% CI 1.04 
to 2.88), consistency of adherence (COR 2.73, 95% CI 1.68 to 4.45) and treatment interruption (COR 9.93, 95% 
CI 4.79 to 20.59) were significantly associated with first line treatment failure (Table 10). 
 
3.7.5 Bivariate analyses of base line BMI  
Regarding to base line BMI, base line BMI <16kg/m2 & 16-18.4 kg/m2 were significantly associated with first 
line antiretroviral treatment failure in a bivariate analysis ((COR 3.8, 95% CI 1.89 to 7.65) & (COR 2.11, 95% 
CI 1.21 to 3.70)) respectively (Table 11). 
 
3.7.6. Bivariate analyses of clinical disease mechanism and other health problems related variables  
From all variables related to clinical disease mechanism & other health problems, WHO stage IV (COR 2.73, 
95% CI 1.12 to 6.64), bed ridden in functional status (COR 5.65, 95% CI 2.29 to 13.90), ambulatory in 
functional status (COR 2.29, 95% CI 1.29 to 4.04), history of OI (COR 3.57, 95% CI 2.05 to 6.23), history of 
pulmonary TB treatment (COR 4.36, 95% CI 2.62 to 7.24), history of chronic gastric problem (COR 13.66,CI 
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5.47 to 34.25), history of chronic diarrhea (COR 9.59, 95% CI 4.00 to 23.02) & taking other medication (COR 
3.08, 95% CI 1.88 to 5.02) were significantly associated with first line antiretroviral treatment failure in a 
bivariate analysis (Table 12). 
 
5.8. Multivariable analyses  
All variables associated with first line treatment failure in the bivariate analysis with P value <.05 were entered 
in a multivariable logistic regression analysis. Finally, baseline CD4 count <50 cell/µl, treatment interruption, 
history of pulmonary TB treatment during HAART follow up time, and history of chronic gastric problem were 
independently associated with first line antiretroviral treatment failure.  
Patients with base line CD4 count below 50cell/µl failed for first line antiretroviral drug 2.7 times than that of 
with >150 cell/microliter with 95% CI 1.24 to 5.64.  
Patients who interrupted treatment through defaulting or other reason were failed for first line antiretroviral drug 
5.4 times than that of not interrupted patients with 95% CI 2.33 to 12.13. While patients having history of 
pulmonary TB treatment during HAART follow up were failed almost 3 times than that of without history with 
95% CI 1.55 to 5.34. Similarly, those patients having history of gastric problem during HAART follow up time 
were failed 6.6 times than that of with no history of gastric problem with 95% CI 2.33 to 18.87 (Table 13). 
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Discussion  
The study has provided an opportunity to find out determinants of first line antiretroviral treatment failure in 
what is globally a very serious challenge for antiretroviral treatment program. In the study, several risk factors of 
first line antiretroviral treatment failure were investigated in adult HIV-infected population in Addis Ababa 
public hospitals. Among base line laboratory measures, base line CD4 count <50 cell/µl was significantly 
associated with first line antiretroviral treatment failure. Patients with base line CD4 count below 50cell/µl failed 
2.7 times than that of with >150 cell/µl with 95% CI 1.24 to 5.64. The result is consistent with other study done 
in South Africa; a baseline CD4 count less than 50 cells per microliter increased the odds of failure more than 5 
folds [29]. Similarly, a study done by Euro SIDA study group had reported the association between lower base 
line CD4 count and treatment outcome or disease progression; despite immunological failure, patients with 
higher pre-HAART CD4+ cell counts would be at less immediate risk of disease progression [5].  
Patients who interrupted treatment through defaulting or other reason were failed 5.4 times than not interrupted 
with 95% CI 2.33 to 12.13. The result is comparable with a study done in South Africa; the odds of treatment 
failure were more than 8 folds for Patients who interrupted treatment through defaulting or non-adherence [30]. 
The very high risk of first line antiretroviral treatment failure in the study in patients with unplanned 
interruptions to therapy raises a concern that the failure to stagger ART cessation may be contributing to 
subsequent treatment failure which is consistent with several previous reports [29, 32].  
However the finding of this study is inconsistent with a study done in Kampala, Uganda; history of unplanned 
treatment interruption was negatively associated with virologic treatment failure (odds ratio, 0.2; 95% 
confidence interval, 0.1–0.6) [35]. This variation might be due to the difference in study design. Other reason 
might be the difference of the stages of failure seen in this study and a study in Uganda; this study includes all 
stages of treatment failure while the Ugandan study was specific to virulogic failure. The effect could be 
potential use of treatment interruptions as a strategy in heavily pretreated patients (e.g., to permit reemergence of 
drug-susceptible virus as a dominant strain), which is not advisable to be considered as a viable option in patients 
with advanced immune suppression at the time of virologic failure [34].  
Chronic gastric problem and pulmonary TB treatment during HAART follow up were significantly associated 
with first line antiretroviral treatment failure in this study. Several studies have shown that other health problems 
other than HIV/AIDS are a strong risk factor for occurrence of first line antiretroviral treatment failure or poor 
treatment success. A comparative study done between low and high income countries showed that those patients 
with comorbidities are at a higher risk of mortality and poor treatment outcome; Eligibility for antiretroviral 
treatment and the need for treatment of tuberculosis should be determined earlier and HAART should be started 
before serious comorbidities develop [42].  
Patients having history of pulmonary TB treatment during HAART follow up failed almost 3 times than that of 
without history with 95% CI 1.55 to 5.34. This finding is inconsistent with a study done in South Africa; 
pulmonary TB treatment was not associated with first line antiretroviral treatment failure [30]. The discrepancy 
might be due to the lower immune status related to poor nutritional status & low socio economic back ground of 
patients in Ethiopia as compared to South Africa. The other reason to be inconsistent between this study and a 
study done in South Africa might be due to the initiation of HAART after serious comorbidities and advanced 
stage of disease had occurred among patients in Ethiopia because of late HIV test and late initiation of HAART. 
There might be also a difference due to sample size variation in this study and South African study. In addition 
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to these, the study done in South Africa is specific to virulogic failure (early stage of treatment failure) though 
this study includes all stages (immunological, clinical or virulogical) failure in defining cases. 40  
Similarly, those patients having history of chronic gastric problem failed 6.6 times than that of with no history of 
gastric problem with 95% CI 2.33 to 18.87. The result is consistent with a study done on gastro intestinal 
problems & HIV on treatment success which showed that gastro intestinal problem was a strong predictor for a 
better treatment outcome; a healthy GI tract is necessary for proper absorption of medications. And controlling 
symptoms like nausea and diarrhea will improve your quality of life and help you adhere to your medications, 
causing better long-term treatment outcomes [42]. 
 
4. CONCLUSION 
Majorities, 55 (53.4%) of cases and 123 (59.7%) of controls were females. Most, 75 (72.8%) of cases and 165 
(80.1%) of controls were orthodox Christian followers. regarding to marital status, 44 (42.7%) of cases and 98 
(47.6%) controls were married. Among cases and controls respectively; the median (interquartile range) baseline 
(at HAART initiation) cd4 count was 74 cells/µl (1–436) and 140 cells/µl (1-667).the independent predictors for 
first line antiretroviral treatment failure were;base line cd4 count lower than 50 cell/µl, unplanned anti-retroviral 
treatment interruption, history of pulmonary treatment during HAART follow up and, history of chronic gastric 
problem were the independent predictors for first line antiretroviral treatment failure. Based on the findings of 
the study the following recommendation is forwarded. health professionals should pay attention not to delay to 
start art for patients having lower cd4 count, close follow up to all patients on art to avoid unplanned treatment 
interruption & consequent problems, patients on pulmonary TB treatment and/or history of TB treatment during 
HAART follow up need further investigation and all HIV infected patients on HAART should be examined for 
all gastro intestinal problems & should be treated subsequently. Finally, further study with regards to quality of 
care given in health institutionswhich are supposed to give ART service, care provider aspect & directly from 
patients’ side should be done in the future. 
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the data were fully guaranteed and the collected data were used only for research purpose. 
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Definition for the term 
Virulogic failure-When Plasma viral load is above 5000 copies/ml it is virulogical failure [19].  
Immunological failure- When CD4 count falls to the base line (below or 50%) from on treatment peak value or 
persistent CD4 level below100 cell/mm3 without concomitant infection to cause transient CD4 cell 
decreasement [19].  
Clinical failure- New or recurrent WHO stage 4 conditions occurred and certain WHO stage 3 conditions 
(pulmonary TB and recurrent bacterial infections) [19]. 
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